View a Chinese translation of this page here
Thorax is one of the world’s leading respiratory medicine journals, publishing clinical and experimental research articles on respiratory medicine, paediatrics, immunology, pharmacology, pathology, and surgery. Thorax seeks to publish significant advances in scientific understanding, which are likely to impact on clinical practice. This includes articles concerning basic and translational mechanisms with application to clinical material (cell and molecular biology, genetics, epidemiology, and immunology).
Thorax offers a fast track review service for high quality papers, authors should discuss this in advance with the Editors’ in Chief.
Thorax adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. To view all BMJ Journal policies please refer to the BMJ Author Hub policies page.
Thorax will not consider for publication any study partly or wholly funded by the tobacco industry, as explained here.
Articles are published under an exclusive licence or non-exclusive licence for UK Crown employees or where BMJ has agreed CC BY applies. For US Federal Government officers or employees acting as part of their official duties, the terms are as stated in accordance with our licence terms. Authors or their employers retain copyright. Open access articles can be reused under the terms of the relevant Creative Commons licence to facilitate reuse of the content; please refer to the Thorax Author Licence for the applicable Creative Commons licences”.
More information on copyright and authors’ rights.
Reviewing for Thorax
Peer review may seem like a thankless task, but without it research would be unreliable. BMJ values reviewers and wants to encourage good standards of review. Information on how to review for any BMJ Journal, and guidance from some of our Editors is available here. If you have any other questions about reviewing, please contact our Editorial team at email@example.com
Tobacco industry funded work
Thorax will not consider for publication papers reporting work funded, in whole or in part, by a tobacco company or tobacco industry organization. Nor will the journal consider papers by authors who accept tobacco industry funding, including funding for research costs, for all or part of any author’s salary, or other forms of personal remuneration. For further information, please read this editorial giving the reasoning behind the journal’s policy. Failure to declare competing interests at submission, or when an article is commissioned, can result in immediate rejection of the paper. If a competing interest comes to light after publication, Thorax will issue a formal correction to or retraction of the whole paper, as appropriate.
Article publishing charges
During submission, authors can choose to have their article published open access for 1,950 GBP (exclusive of VAT for UK and EU authors). There are no submission, page or colour figure charges.
For more information on open access, funder compliance and institutional programmes please refer to the BMJ Author Hub open access page.
Thorax adheres to BMJ’s Tier 2 data policy. We strongly encourage that data generated by your research that supports your article be made available as soon as possible, wherever legally and ethically possible. We also require data from clinical trials to be made available upon reasonable request. To adhere to ICMJE guidelines, we require that a data sharing plan must be included with trial registration for clinical trials that begin enrolling participants on or after 1st January 2019. Changes to the plan must be noted in the Data Availability Statement and updated in the registry record. All research articles must contain a Data Availability Statement. For more information and FAQs, please see BMJ’s full Data Sharing Policy page.
Thorax mandates ORCID iDs for the submitting author at the time of article submission; co-authors and reviewers are strongly encouraged to also connect their ScholarOne accounts to ORCID. We strongly believe that the increased use and integration of ORCID iDs will be beneficial for the whole research community.
Please find more information about ORCID and BMJ’s policy on our Author Hub.